Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data
Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data
On Sunday, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) presented results from the KARDIA-2 Phase 2 study, which evaluated the efficacy and safety of a single subcutaneous dose of zilebesiran when added to one of three standard-of-care antihypertensives.
週日，Alnylam Pharmicals Inc.（納斯達克股票代碼：ALNY）公佈了 KARDIA-2 二期研究的結果，該研究評估了將單劑量皮下劑量的齊萊貝西蘭添加到三種標準護理抗高血壓藥物之一時的療效和安全性。
The company announced the topline results from the KARDIA-2 study in March 2024.
該公司於 2024 年 3 月公佈了 KARDIA-2 研究的主要結果。
When added to the standard of care, indapamide and, amlodipine, zilebesiran respectively achieved reductions of 12.1 mmHg (p<0.001) and 9.7 mmHg (p<0.001) in the primary endpoint of change from baseline in 24-hour mean systolic blood pressure at three months.
將吲達帕胺和氨氯地平添加到護理標準中後，三個月時24小時平均收縮壓變化的主要終點分別降低了12.1 mmHg（p
However, when added to olmesartan, the experimental drug delivered a 4 mmHg reduction, missing statistical significance (p=0.036).
但是，當添加到奧美沙坦中時，該實驗藥物降低了4 mmHg，缺少統計學意義（p=0.036）。
Similarly, when added to the standard of care, indapamide and, amlodipine, zilebesiran, respectively, achieved reductions of 11.0 mmHg (p<0.001) and 7.9 mmHg (p<0.001) in the change from baseline in 24-hour mean systolic blood pressure at six months.
同樣，當添加到護理標準時，吲達帕胺和氨氯地平、齊樂貝西蘭在六個月時與基線相比的變化分別降低了11.0 mmHg（p
However, statistical significance was missed in the olmesartan arm, with a reduction of 1.6 mmHg (p=0.26).
但是，奧美沙坦組的統計學意義不大，下降了1.6 mmHg（p=0.26）。
Alnylam Pharmaceuticals and its partner Roche Holdings AG (OTC:RHHBY) have initiated a Phase 2 KARDIA-3 study of zilebesiran on top of 2-4 anti-hypertensive medicines and are planning a Phase 3 CVOT, JMP Securities writes.
JMP Securities寫道，Alnylam Pharmicals及其合作伙伴羅氏控股股份公司（場外交易代碼：RHHBY）在2-4種抗高血壓藥物的基礎上啓動了對齊勒貝西蘭的第二階段 KARDIA-3 研究，並計劃進行第三階段CVOT。
The analyst recommends owning Alnylam shares ahead of HELIOS-B data on AMVUTTRA in ATTR-CM in late June or early July. If positive, Alnylam will file the FDA marketing application by the end of 2024 and use a priority review voucher for approval in 2H 2025.
該分析師建議在6月下旬或7月初ATTR-CM公佈AMVUTTRA的HELIOS-B數據之前持有Alnylam的股票。如果陽性，Alnylam將在2024年底之前提交美國食品藥品管理局的上市申請，並在2025年下半年使用優先審查券獲得批准。
JMP reiterates the Overweight rating, with a price target of $217.
JMP重申增持評級，目標股價爲217美元。
William Blair writes that although there could be noise in interpreting the Olmesartan cohort of KARDIA-2, the zilebesiran data is strong here and has invoked genuine interest.
威廉·布萊爾寫道，儘管在解釋奧美沙坦的 KARDIA-2 隊列時可能會有噪音，但這裏的 zilebesiran 數據非常強勁，引起了人們的真正興趣。
With approximately 219 million patients in seven key markets, the primary hypertension market is substantial, making the zilebesiran market significant for Alnylam financially.
在七個關鍵市場擁有約2.19億名患者，原發性高血壓市場龐大，這使得zilebesiran市場對Alnylam來說意義重大。
While investor attention is on the HELIOS-B cardiovascular outcomes trial for vutrisiran in TTR-cardiomyopathy, expected in June or early July,
儘管投資者的注意力集中在預計於6月或7月初進行的針對Vutrisiran治療TTR心肌病的HELIOS-B心血管結果試驗上，
Alnylam is actively progressing its RNA-targeted therapeutics pipeline. Therefore, William Blair maintains the Outperform rating on Alnylam.
Alnylam正在積極推進其RNA靶向療法產品線。因此，威廉·布萊爾維持對Alnylam的跑贏大盤評級。
Price Action: ALNY shares are up 2.46% at $157.34 on the last check Monday.
價格走勢：在週一的最後一次支票中，ALNY股價上漲2.46％，至157.34美元。
譯文內容由第三人軟體翻譯。